Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

IQ Explains Some Of The Difference In Heart Disease Between People Of High And Low Socio-economic Status
A unique study looking at the difference in cardiovascular disease (heart disease and stroke) and life expectancy between people of high and low socio-economic status has found that a person"s IQ may have a role to play.

GENEART Supports The UK HIV Vaccine Consortium (UK HVC) In Developing A DNA Vaccine Candidate Against HIV
GENEART AG, global leader in gene synthesis and specialist in the field of Synthetic Biology, announces being awarded a contract for the design and production of two DNA vaccine candidates against HIV by the UK HVC. The genes (blueprints for virus proteins), optimized and customized by GENEART, are to be used as basis for clinical studies.
News of the day
BioMçİrieux Announces AOAC-RI Certification Of Its New VIDAS(R) UP E. Coli O157 (Including H7 Strain) Detection Kit
bioMçİrieux (Paris:BIM), a world leader in the field of in vitro diagnostics, announced that an AOAC-RI certification has been granted (No. 060903) to the VIDAS® UP E. coli O157 (Including H7) method for screening beef, selected produce and irrigation water. Food manufacturers in the U.S. and many other countries rely on AOAC-RI certified testing methods to release their products on the market. The new solution is based on recombinant phage protein, the latest technology available for food pathogen screening, which offers unique specificity and sensitivity. E. coli O157:H7 is a potentially lethal strain of Escherichia coli that has caused many food outbreaks in the United States, Canada, Japan, and Europe.
Nutrition

All Global Announces Panel Expansion In The U.S. And Europe

All Global, the world"s leading global healthcare data collection agency, announced the integration of the TNS JStreet panel into its All Global online physician panel across the U.S. and Europe. With this integration, All Global will boost its number of active physician participants by 50% across key specialties, including oncology, cardiology, neurology and hematology. The combined panel increases All Global"s reach into major markets throughout the U.S. and Europe to support the pharmaceutical industry"s growing need for multi-country insights. All Global also is currently extending its coverage into new emerging countries to meet the research goals of companies focused on these evolving growth areas. All Global continues to offer a centralized service model to coordinate global res while utilizing local knowledge and expertise. "This global panel integration is a big step forward for All Global. Our increased coverage across key specialties and geographies enables us to help clients meet their dual need for both larger sample sizes and greater sample specificity," says Tony Burke, CEO, All Global. "In addition, we have enhanced our core focus of delivering high-quality physician data across global markets while also providing local healthcare expertise. All Global remains committed to advancing and diversifying our offerings for the benefit of the healthcare market research community." The All Global physician panel is available to market research companies and agencies worldwide. It is used to support ad hoc custom, tracking and syndicated market research projects, as well as the All Global Quick-Turn product suite. "We are bringing together two of the industry"s most respected and highest quality physician panels," says Terence McCarron, EVP Global Business Development for All Global. "Launched between 1999 and 2002, both panels were pioneers in the healthcare market research industry. Now combined, this panel expansion reflects All Global"s ongoing commitment to growth and flexibility, so we can best meet our clients" evolving needs." All Global


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

İ Copyright 2009